Lanthanum Composition

Matrix Laboratories Limited
Granted App No 737/CHE/2008 Patent 274796 Pharmaceuticals

Patent information

IP India · live record
Application number
737/CHE/2008
Filing date
26 March 2008
Status
Granted
Legal status
Inforce
Publication number
40/2009
Publication type
INA
Invention field
Pharmaceuticals
Patent number
274796
Grant date
09 August 2016
Next renewal due
26 March 2027

Abstract

NOT AVAILABLE

Applicants

1
India
MATRIX LABORATORIES LIMITED 1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD, SECUNDERABAD - 500 003.

Inventors

9
India
AMMINABAVI, NAGARAJ1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD, SECUNDERABAD - 500 003.
India
JAIN, SATISHKUMAR1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD, SECUNDERABAD - 500 003.
India
GORE, SUBHASH1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD, SECUNDERABAD - 500 003.
India
GUDIPATI, GNANADEVA CHALAPATHY1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD, SECUNDERABAD - 500 003.
India
CHINNU, BALAKRISHNAN1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD, SECUNDERABAD - 500 003.
India
IYER, SUBRAMANIAN1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD, SECUNDERABAD - 500 003.
India
P. MANOJ KUMAR1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD, SECUNDERABAD - 500 003.
India
GUPTA, RAJESH S1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD, SECUNDERABAD - 500 003.
India
INDU, BHUSHAN1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD, SECUNDERABAD - 500 003.

Specification

Show full textCollapse

Field of invention:

The present invention relates to solid oral pharmaceutical composition containing Lanthanum carbonate and process to make the same.

Background of the invention and related prior art:

Oral ingestion is one of the primary routes used for drug administration. This route provides a convenient method of effectively achieving both local and systemic effects. The properties of Lanthanum make it a good candidate as a phosphate binder. It has a high affinity for binding phosphorous and in the form of its carbonate salt, has a low solubility that limits gastrointestinal absorption. In the presence of HC1 acid in the stomach, a proportion of administered Lanthanum carbonate is converted to the more highly soluble chloride salt with the release of carbon dioxide.

The commercially available composition of Lanthanum is a chewable tablet and is marketed under the brand name of FOSRENOL® in strengths of 500mg, 750mg and 1000mg strengths, FOSRENOL® inhibits absorption of phosphate by forming highly insoluble Lanthanum phosphate complexes, consequently reducing both serum phosphate and calcium phosphate product. In vitro studies have shown that in the physiologically relevant pH range of 3 to 5 in gastric fluid, Lanthanum binds approximately 97% of the available phosphate when Lanthanum is present in a two-fold molar excess to phosphate.

A stable pharmaceutical composition does not exhibit substantial decomposition of the active pharmaceutical ingredient during the time between the manufacture of the composition and its use by a patient. Lanthanum carbonate and a number of other drugs suffer from instability problems because the active pharmaceutical ingredient rapidly degrades in the presence of water or moisture. Lanthanum carbonate compositions tend to degrade, with formation of lanthanum hydroxycarbonate.

Palatability and "mouth feel" are extremely important factors in formulating high dose insoluble drugs, especially, if the composition is intended to be a chewable formulation. Insoluble materials usually have both an unpleasant mouth feel and an unpalatable taste due to chalkiness, grittiness, & dryness properties of these materials.

It is known that tablet blends may be dry mixed, dry-granulated or wet-granulated before tableting. The choice of the processing procedure viz., (dry mixing, dry granulation, wet granulation) depends on the properties of the drug and the chosen excipients. Generally, a dry manufacturing process is thought to be preferable for moisture-sensitive drugs. JP 62-145024 discloses Lanthanum carbonate. Example 11 therein discloses La2(C03)3 H2O, i.e. the monohydrate.

U.S. patent No 5,968,976 discloses pharmaceutical compositions for the treatment of hyperphosphataemia comprising Lanthanum carbonate hydrate where Lanthanum has three to six molecules of water. This document states that certain forms of Lanthanum carbonate exhibit improved performance i.e. higher phosphate removal, specifically Lanthanum carbonates having 3 to 6 molecules of water per molecule of Lanthanum carbonate, over then available standard commercial Lanthanum carbonate, which the inventors believed was the octahydrate form, and over La2(C03)3 H2O i.e. monohydrate form or similar compounds.

U.S. patent No 7,192,609 and US 2007/116782 disclose a method of preventing or treating urolithiasis i.e. kidney stones using nontoxic sahs of rare earth metal ions e.g.. Lanthanum salts, to bind dietary oxalate and preventing its absorption into the gastrointestinal tract. They also disclose that the hydration state of the Lanthanum salt is important; especially hydrates with waters of hydration of less than 7 moles water per mole of salt, and preferably the salts should contain 3 to 5 moles of water.

U.S. patent No 7,381,428 discloses stabilized Lanthanum carbonate compositions, essentially prepared by dry mixing and compression of Lanthanum carbonate and stabilizers along with pharmaceutically acceptable additives, where monosaccharide or disaccharides are used as stabilizing agent to control/ avoid the generation of hydroxycarbonate impurity in the composition.

U.S. application No: 2005/0079135 discloses chewable pharmaceutical compositions, containing Lanthanum carbonate having 3 to 8 molecules of water and the process of making pharmaceutical composition which involve dry mixing the ingredients and directly compressing the powder mixture or a slugging method or a roller compaction method.

These afore-mentioned prior art can be summarized as follows:

a) Lanthanum carbonate having a hydration between 3 to 6 water molecules is preferred;

b) Avoidance of water/ wet granulation and a preference towards dry methods -compaction/ direct compression is noticed;

c) Monosaccharide or disaccharide excipients are the preferred stabilizing agents to avoid / lower generation of hydroxycarbonate impurity.

There is a need in the art to provide stable and cost effective oral pharmaceutical composition comprising Lanthanum carbonate, where the composition is prepared utilizing alternative techniques and still prevents degradation of Lanthanum carbonate as current regulatory requirements preclude detectable decarboxylation for administration to patients.

The present invention is based on the finding that a stable, effective solid oral dosage form of Lanthanum carbonate can be prepared even with wet granulation technique and a high hydration state Lanthanum carbonate drug. Lanthanum carbonate used in the instant invention is in high hydration state, but still the composition prepared according the invention has comparable or higher in-vitro phosphate binding, as that of FOSRENOL.

The composition prepared according to the invention has a high load of Lanthanum carbonate, approximately more than 60% by weight of the composition, preferably between 65% to about 80% by weight of the composition. Also, a finer sized lanthanum carbonate is practically preferred for use in the composition. Drug particles having d (0.9) not more than 110 microns are preferred.

Objects of the invention;

The present invention is related to a stable, solid oral composition comprising Lanthanum carbonate having more than six molecules of water per molecule of lanthanum carbonate, preferably eight molecules of water and a carrier or diluent wherein such diluent does not include a monosaccharide or a disaccharide, with a comparable or higher in vitro Phosphate binding capability to that of commercially available brand FOSRENOL®.

It is an object of the present invention is to provide a stable pharmaceutical composition of Lanthanum carbonate having more than six molecules of water per molecule of lanthanum carbonate- preferably eight molecules- and pharmaceutically acceptable diluents/ carriers, prepared by wet granulation technique, wherein the composition is devoid of monosaccharide and/ or disaccharides as stabilizers.

Another object of the present invention is to provide a stable pharmaceutical composition of Lanthanum carbonate preferably in octahydrate form, where the composition has high drug loading, preferably more than 65% by weight of the composition.

Another object of the present invention is to provide a stable pharmaceutical composition comprising Lanthanum carbonate, wherein the Lanthanum carbonate used has a particle size distribution such that d(0.9) is not more than 110 microns, preferably not more than 80 microns.

In one embodiment of the invention, the pharmaceutical composition is prepared by a process comprising:

(a) blending Lanthanum carbonate, at least one carrier or diluent and optionally other pharmaceutically acceptable excipients and granulating said mixture with a binder solution to form granulate;

(b) screening the granules and blending the granules with a lubricant; and

(c) compressing the blend of step [c] to form tablets.

In a preferred embodiment of the invention, a lanthanum carbonate composition is prepared by wet granulation process comprising the drug in its octahydrate form such that it constitutes more than 65% weight by weight of the composition, with a drug particle size such that d(0.9) is below 110 microns and a carrier/ diluent wherein such diluent does not include a monosaccharide or a disaccharide.

In another embodiment, the invention relates to a method for treating hyperphosphatemia in a renal failure patient, controlling hyperparathyroidism in a patient with chronic renal insufficiency, controlling hyperparathyroidism in a patient with chronic renal insufficiency, comprising administering a composition prepared in accordance with the invention, described herein.

SUMMARY OF THE INVENTION

The invention provides stable Lanthanum carbonate compositions and methods for their preparation. In one aspect, the present invention provides a stable solid oral composition comprising: a) Lanthanum carbonate in high hydration state; b) at least one pharmaceutically acceptable carrier or diluent, wherein the carrier or diluent excludes a monosaccharide or a disaccharide and wherein the composition exhibits comparable or higher in vitro Phosphate binding capability to that of commercially available brand FOSRENOL®.

In a preferred embodiment of the invention, a lanthanum carbonate composition comprising the drug in its octahydrate form such that it constitutes more than 65% weight by weight of the composition, with a drug particle size such that d(0.9) is below 110 microns, preferably below 80 microns and a carrier/ diluent wherein such diluent does not include a monosaccharide or a disaccharide. An additional aspect of the preferred embodiment envisages use of wet granulation technique for making the composition. As presently contemplated, in one broad form, the invention provides a process to make a pharmaceutical formulation comprising the following steps:

(a) blending Lanthanum carbonate, at least one carrier or diluent [wherein the carrier or diluent is not a monosaccharide or a disaccharide] and optionally other pharmaceutically acceptable excipients and granulating the mixture with a binder solution to form granules;

(b) screening the granules and blending the granules with a lubricant, and

(c) compressing the blend of step [c] to form tablets.

Other aspect of the present invention includes use of this composition for the treatment of a disease or disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compositions of the present invention.

Brief description of the flgures:

Figure 1: Accelerated XRD Stability for composition of Example 1; Figure 2: Accelerated XRD Stability for composition of Example 4;

Figure 3: Comparative dissolution for compositions of Example 7 v/s Example 8. General comment for ail threti figures:

The XRD peaks depicted, »lplhiabeti««Uy represent the following: A - Hydroxycarbonaie, B - Lanthanum Carbonat«r C - Lanthanum Carboriatc chc';/able taijlets, Initial sample D - Lanthanum Carbonati; che';vable ts.blets, after three month at 407 75% RH sample E - Placebo Comment for Fig. 1 & 2

The XRD data clearly revealed that i.Euathanum carbonate chewable tablet is stable and the decarboxylation of lar dhanum carbonate was not seen over the entire length of experiment, evcsn aftei stoniag the compositions at accelerated condition for thee month. Comment for Fig. 3;

The release profile obtained pi'oves tliat the chewable tablets containing lanthanum carbonate having d (0.9) aboir: 250 micron is comparatively dissolving slower than tablets containing lanthanum c irbonatc having d (0,9) not more than 105 micron. Detailed description includim; preferred embodimenta of the invegtion;

Generic drug manufactures constantly strive to create compositions that exhibit similar in-vitro and iri-vivo jirofile as that of Innovator drug composition. The present inventors have laow formuJiilcd a Lanthanum compositioa that contains Lemthanum Carbonate salt in !aigh hidration state but still has comparable in-vitro phosphate binding capacity, to that of commercially available brand FOSRENOL® which contains Lanthanum Carbonate in low hydration state. The in-vitro phosphate binding have shown that the compositions of the present invention have equal or higher phosphate binding capacity to that of FOSRENOL®.

The present invention is directed to a formulation and a process for obtaining such composition. It should be noted that the hydration state of the Lanthanum compound present in the formulation of the present invention is relevant to the biological properties of the product as also the possibility of degradation of drug product to its hydroxycarbonate form. The prior art advises that for getting optimum phosphate binding, composition containing Lanthanum carbonate must have Lanthanum in preferably low hydration state.

In an effort to overcome the unpleasant mouth feel and an unpalatable taste due to chalkiness, grittiness & dryness properties of lanthanum carbonate, the inventors have employed Lanthanum carbonate having particle size d (0.9) not more than 110 microns, preferably not more than 80 microns. The particle size distribution of Lanthanum carbonate was determined by using Malvern analyzer.

The active agent in composition according to the invention is present in the amount of from 250 - 1000 mg e.g. 250mg, 500 mg, 750 mg or 1000 mg. Approximately 2140 mg of Lanthanum carbonate octahydrate corresponds to 1000 mg of elemental lanthanum.

As used herein, a "stable composition" or "stabilized composition" or "stabilized lanthanum carbonate composition" refers to a composition containing lanthanum carbonate (of high hydration state) and one or more diluents or carriers excluding monosaccharides or disaccharides. The lanthanum carbonate in a stabilized lanthanum carbonate composition degrades into lanthanum hydroxycarbonate at a slower rate compared to lanthanum carbonate alone or not in the presence of other materials.

Lanthanum carbonate in high hydration state for the present invention means Lanthanum carbonate salt having more than six molecules of water, in between seven to ten, and preferably eight molecules of water i.e. octahydrate form of Lanthanum carbonate.

The composition may further comprise pharmaceutically acceptable additives known in the art. The term 'pharmaceutically acceptable additive' includes 'pharmaceutically acceptable excipient' within its ambit and the singular term includes plural as well. The pharmaceutically acceptable excipients may be one or more of diluents, binders, surfactants, lubricants, glidants, amino acids, sweetening agents, coloring agents and flavoring agent, such that no monosaccharide or disaccharides are used in the composition.

The term "diluent" or "carrier" as used herein is intended to mean inert substances used as carriers to create the desired bulk, flow properties, and compression characteristics in the preparation of tablets and capsules, excluding monosaccharide and disaccharide based excipients or stabilizers. Acceptable carriers or diluents include, but are not limited to, amino acids, Avicel pH 102, calcium carbonate, calcium phosphate-dibasic, calcium phosphate-tribasic, calcium sulfate, mannitol, microcrystalline cellulose, silicified microcrystalline cellulose, powdered cellulose, and the like can be used. The pharmaceutically inert diluent may be used in an amount of about 15% to about 25% by weight of the total weight of the dosage form.

The term "binder/ granulating agent" is intended to mean substances used to cause adhesion of powder particles in tablet granulations. Suitable binders according to the present invention can be selected from, alkyl celluloses such as methyl cellulose, ethyl cellulose, hydroxyalkyl celluloses such as hydroxypropyl cellulose, low substituted hydroxypropyl cellulose, hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, microcrystalline cellulose, gelatin, polyvinylpyrrolidone and eudragits.

Examples of suitable granulating fluids employed in the preparation of present composition include water, methylene chloride, isopropyl alcohol, acetone, methanol, ethanol and the like. The preferred granulating fluid is water.

Glidants improve the flowability of the powder making up the tablet during production. Glidants can be selected from selected from the group consisting of: silicon dioxide, colloidal silicon dioxide, fumed silicon dioxide, sodium aluminosilicate, calcium silicate, powdered cellulose, microcrystalline cellulose, corn starch, sodium benzoate, calcium carbonate, magnesium carbonate, asbestos free talc, metallic stearates, calcium stearate, magnesium stearate, zinc stearate, Stearowet C, magnesium lauryl sulfate, or magnesium oxide, where colloidal silicon dioxide is the preferred glidant.

The term "lubricant" as used herein is intended to mean substances used in tablet formulations to reduce friction during tablet compression. Suitable lubricants according to the present invention can be selected from calcium stearate, magnesium stearate, sodium lauryl sulfate, talc, mineral oil, stearic acid, zinc stearate, colloidal silicon dioxide, glyceryl behenate, polyethylene glycol, sodium stearyl fumarate, hydrogenated cottonseed oil, sodium benzoate, leucine or combinations thereof and other such materials known to those of ordinary person skilled in the art.

Amino acids include one or more compounds selected from alanine, arginine, aspartic acid, asparagine, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine; preferably glycine and lysine.

Sweetening agents may be selected from a wide range of materials such as water-soluble sweetening agents, water-soluble artificial sweeteners, and dipeptide based sweeteners, including mixtures thereof. Specific examples of sweeteners that can be included but are not limited to are Acesulfame potassium, calcium saccharinate, ammonium cyclamate, ammonium glycirhizinate, aspartame (N-L-a-aspartyl-L-phenylalanine 1 -methylester).

The amount of each type of additive employed, e.g. carrier or diluent, binder, glidant and lubricant may vary within ranges known to be conventional in the art.

In a preferred embodiment, there is provided a process to make a pharmaceutical formulation comprising the following steps:

(a) blending Lanthanum carbonate, at least one carrier or diluent and optionally other pharmaceutically acceptable excipients and granulating said mixture with a binder solution to form granules,

(b) screening the granules of step [a] and blending them with magnesium stearate, and

(c) compressing the blend of step [b] to form tablets.

The compression of granules to tablets is carried out in a conventional manner.

The pharmaceutical composition of the present invention is stable; having comparable in vitro Phosphate binding capability to that of commercially available brand FOSRENOL®. The invention also contemplates reducing the amount of lanthanum hydroxycarbonate impurity generated, especially under formulation and extended storage conditions. There is, therefore, a concomitant reduction in unit cost, as the composition is prepared by inexpensive wet granulation technique, generation of low impurity and the composition possess comparable in vitro Phosphate binding capability to that of FOSRENOL®.

1. All the ingredients were shifted through mechanical sifter fitted with suitable mesh size.

2. Ingredients like Lanthanum carbonate, glycine. Avicel CE 15, Acesulfame K, prosolve, and Sodium CMC were loaded in to the Rapid mixture granulator and dry mixed for 10 minute under Impeller slow speed and chopper off.

3. Binder solution was prepared by dissolving HPC in purified water under continues stirring to get clear solution.

4. Step 2 was granulated using the binder solution of step 3 in to the Rapid mixture granulator for 10 minute under Impeller slow speed and chopper off.

5. Wet granules were dried to achieved required LOD and milled using Quadra-co mill fitted with suitable mesh size

6. Granules of Step 5 were blended with the Talc, colloidal silicon dioxide, magnesium stearate and microcrystalline cellulose in bin blender for the period of 10 minutes.

7. Lubricated blend of step 6 was compressed using suitable tooling.

Manufacturing Process:

1. All the ingredients were shifted through mechanical sifter fitted with suitable mesh size.

2. Ingredients like Lanthanum carbonate, Avicel CE 15, Acesulfame K, colloidal silicon dioxide and Microcrystalline cellulose( Part I) were loaded in to the Rapid mixture granulator and dry mixed for 10 minute under Impeller slow speed and chopper off.

3. Binder solution was prepared by dissolving HPC in purified water under continues stirring to get clear solution.

4. Step 2 was granulated using the binder solution of step 3 in to the Rapid mixture granulator for 10 minute under Impeller slow speed and chopper slow.

5. Wet granules were dried to achieved required LOD and milled using Quadra-co mill fitted with suitable mesh size

6. Granules of Step 5 were blended with the magnesium stearate and microcrystalline cellulose (Part II) in bin blender for the period of 10 minutes.

7. Lubricated blend of step 6 was compressed using suitable tooling.

Manufacturing Process:

1. All the ingredients were shifted through mechanical sifter fitted with suitable mesh size.

2. Ingredients like Lanthanum carbonate, glycine. Avicel CE 15, Acesulfame K, colloidal silicon dioxide, and microcrystalline cellulose were loaded in to the Rapid mixture granulator and dry mixed for 10 minute under Impeller slow speed and chopper off.

3. Binder solution was prepared by dissolving HPC in purified water under continues stirring to get clear solution.

4. Step 2 was granulated using the binder solution of step 3 in to the Rapid mixture granulator for 10 minute under Impeller slow speed and chopper off.

5. Wet granules were dried to achieved required LOD and milled using Quadra-co mill fitted with suitable mesh size

6. Granules of Step 5 were blended with the magnesium stearate in bin blender for the period of 10 minutes.

7. Lubricated blend of step 6 was compressed using suitable tooling.

Manufacturing Process:

1. All the ingredients were shifted through mechanical sifter fitted with suitable mesh size.

2. Ingredients like Lanthanum carbonate, Avicel CE 15, Acesulfame K, colloidal silicon dioxide and Microcrystalline cellulose( Part I) were loaded in to the Rapid mixture granulator and dry mixed for 10 minute under Impeller slow speed and chopper off.

3. Binder solution was prepared by dissolving HPC in purified water under continues stirring to get clear solution. 4. Step 2 was granulated using the binder solution of step 3 in to the Rapid mixture granulator for 10 minute under Impeller slow speed and chopper slow.

5. Wet granules were dried to achieved required LOD and milled using Quadra-co mill fitted with suitable mesh size

6. Granules of Step 5 were blended with the magnesium stearate and microcrystalline cellulose (Part II) in bin blender for the period of 10 minutes.

7. Lubricated blend of step 6 was compressed using suitable tooling.

Manufacturing procedure:

1. Lanthanum carbonate octahydrate was mixed with Intragranular excipients and sifted through sifter fitted with screen #30,

2. Blend of Step 1 was loaded in to RMG and mixed for 10 minutes.

3. Preparation of binder solution: Hydroxypropyl cellulose is added to purified water under continues stirring to get clear solution

4. The Step -2 is granulated using binder solution of step- 3 in RMG to get required wet mass of powder blend

5. The wet mass of step 4 was sifted through sifter fitted with screen #16, 6. Wet granules are dried for sufficient period time to get LOD between 2 to 4% at 60°C.

7. Dried granules of step -6 is sifted through sifter fitted with screen # 20,

8. The granules blend of Step -7 was blended with the extragranular ingredients in bin blender for 10 minutes.

9. Blend of step -8 is compressed using 24 mm round punches and corresponding dies.

Manufacturing procedure:

1. Lanthanum carbonate octahydrate was mixed with Intragranular excipients and sifted through sifter fitted with screen #30,

2. Blend of Step 1 was loaded in to RMG and mixed for 10 minutes.

3. Preparation of binder solution : Hydroxypropyl cellulose is added to purified water under continues stirring to get clear solution

4. The Step -2 is granulated using binder solution of step- 3 in RMG to get required wet mass of powder blend

5. The wet mass of step 4 was sifted through sifter fitted with screen # 16,

6. Wet granules are dried for sufficient period time to get LOD between 2 to 4% at 60°C.

7. Dried granules of step -6 is sifted through sifter fitted with screen # 20,

8. The granules blend of Step -7 was blended with the extragranular ingredients in bin blender for 10 minutes.

9. Blend of step -8 is compressed using 24 mm round punches and corresponding dies.

Manufacturing Process:

1. All the ingredients were shifted through mechanical sifter fitted with suitable mesh size.

2. Ingredients like Lanthanum carbonate, Avicel CE 15, Acesuifame K, colloidal silicon dioxide and Microcrystalline cellulose( Part I) were loaded in to the Rapid mixture granulator and dry mixed for 10 minute under Impeller slow speed and chopper off 3. Binder solution was prepared by dissolving HPC in purified water under continues stirring to get clear solution.

4. Step 2 was granulated using the binder solution of step 3 in to the Rapid mixture granulator for 10 minute under Impeller slow speed and chopper slow.

mill fitted with suitable mesh size

6. Granules of step 5 were blended with the magnesium stearate and microcrystalline cellulose (Part II) in bin blender for the period of 10 minutes.

7. Lubricated blend of step 6 was compressed using suitable tooling.

Manufacturing Process:

1. All the ingredients were shifted through mechanical sifter fitted with suitable mesh size.

2. Ingredients like Lanthanum carbonate, Avicel CE 15, Acesulfame K, colloidal silicon dioxide and Microcrystalline cellulose( Part I) were loaded in to the Rapid mixture granulator and dry mixed for 10 minute under Impeller slow speed and chopper off.

3. Binder solution was prepared by dissolving HPC in purified water under continues stirring to get clear solution.

4. Step 2 was granulated using the binder solution of step 3 in to the Rapid mixture granulator for 10 minute under Impeller slow speed and chopper slow.

5. Wet granules were dried to achieved required LOD and milled using Quadra-co mill fitted with suitable mesh size

6. Granules of Step 5 were blended with the magnesium stearate and microcrystalline cellulose (Part II) in bin blender for the period of 10 minutes. 7. Lubricated blend of step 6 was compressed using suitable tooling.

Manufacturing Process:

1. All the ingredients were shifted through mechanical sifter fitted with suitable mesh size.

2. Ingredients like Lanthanum carbonate, avicel CE 15, acesulfame K, colloidal silicon dioxide and microcrystalline cellulose( Part I) were loaded in to the Rapid mixture granulator and dry mixed ft)r 10 minute under Impeller slow speed and chopper off.

3. Binder solution was prepared by dissolving hydroxypropyl cellulose in purified water under continues stirring to get clear solution.

4. Step 2 was granulated using the binder solution of step 3 in to the Rapid mixture granulator for 10 minute under Impeller slow speed and chopper slow.

5. Wet granules were dried to achieved required LOD and milled using Quadra-co mill fitted with suitable mesh size

6. Granules of step 5 were blended with the magnesium stearate and microcrystalline cellulose (Part II) in bin blender for the period of 10 minutes.

7. Lubricated blend of step 6 was compressed using suitable tooling.

Manufacturing Process:

1. All the ingredients were shifted through mechanical sifter fitted with suitable mesh size.

2. Ingredients like Lanthanum carbonate, Avicel CE 15, Acesulfame K, colloidal silicon dioxide and Microcrystalline cellulose( Part I) were loaded in to the Rapid mixture granulator and dry mixed for 10 minute under Impeller slow speed and chopper off.

3. Binder solution was prepared by dissolving HPC in purified water under continues stirring to get clear solution.

4. Step 2 was granulated using the binder solution of step 3 in to the Rapid mixture granulator for 10 minute under Impeller slow speed and chopper slow.

5. Wet granules were dried to achieved required LOD and milled using Quadra-co mill fitted with suitable mesh size

6. Granules of Step 5 were blended with the magnesium stearate and microcrystalline cellulose (Part II) in bin blender for the period of 10 minutes.

7. Lubricated blend of step 6 was compressed using suitable tooling. Stability Studies:

Stability study of Lanthanum carbonate chewable tablets , 1000 mg was carried out in sealed HDPE container and this sealed HDPE containers were stored in accelerated stability condition at 40°C/ 75% relative humidity and XRD was performed on tablets withdrawn at specified internals of 1, 2 and 3 months. The XRD graphs are depicted in Figure 1 and 2, summarizing the stability test results of example 1 and example 4. No decarboxylation of Lanthanum carbonate was seen over the entire length of experiment and which is confirmed by the absence of Lanthanum hydroxycarbonate peak in the XRD graphs.

Phosphate Binding Study:

Fosrenol Tablets® Vs. Lanthanum Carbonate Octahydrate chewable tablets

• Phosphate binding studies were done in 100 mM (P04)'^ solution at room temperature.

• Sample is weighed equivalent to 134 mg of elemental Lanthanum

• After adding the sample in 50 ml of Phosphate ion solution shaken for 10 minutes and pH was adjusted by adding 0.1 N HCl or 1 N NaOH to the desired pH.

• The slurry was shaken for two hours with the aid mechanical shaker and then filtered.

• Then phosphate binding was estimated using making a complex with the reagents to yield graded color response depending upon the amount of (P04)""^ present in the filtrate. (Reagents used were Ammonium Molybdate and Ascorbic acid)

• Phosphate binding capacity (mmol/g) determined by calculating un-reacted phosphate in the solution.

Comparative dissolution study of Example 7 Vs. Example 9:

The dissolution test was carried out using modified USP III apparatus at 10 DPM, 900 ml of pH 0.25N HCl at 37 ± 0.5 °C,

Example 7: Formulation containing Lanthanum carbonate having particle size distribution d (0.9) about 105 microns

Example 8: Formulation containing Lanthanum carbonate having particle size distribution d (0.9) about 250 microns

Assessment of Lanthanum Carbonate Chewable Tablets for Chalkiness, Grittiness and Dryness:

The selected panel of 12 healthy human volunteers was requested to taste the chewable lanthanum carbonate tablets by keeping in the mouth till they disintegrated and rank it on a scale of perception ranging from 0-5.

Example 7: Formulation containing Lanthanum carbonate having particle size distribution d (0.9) about 105 micron.

Example 8: Formulation containing Lanthanum carbonate having particle size distribution d (0.9) about 250 micron.

Claims

1. A pharmaceutical composition for the treatment of hyperphosphataemia comprising lanthanum carbonate having more than six molecules of water per molecule of lanthanum carbonate and a pharmaceutically acceptable carrier or diluent, wherein said carrier or diluent excludes monosaccharide/s or disaccharide/s.

2. A pharmaceutical composition prepared by wet granulation comprising:

a) more than 65% weight by weight of lanthanum carbonate having more than 6 molecules of water per molecule of lanthanum carbonate and b) a pharmaceutically acceptable diluent or carrier wherein said carrier or diluent excludes monosaccharide/s or disaccharide/s.

3. A lanthanum carbonate pharmaceutical oral composition prepared by wet granulation process comprising:

a) more than 65% weight by weight of lanthanum carbonate having more than six molecules of water per molecule of lanthanum carbonate with a particle size distribution such that d (0.9) is not more than 110 microns;

b) a pharmaceutically acceptable diluent or carrier except monosaccharide/s or disaccharide/s; and wherein said composition exhibits comparable or higher phosphate binding capacity to that of commercially available FOSRENOL®.

4. A lanthanum carbonate oral composition comprising:

a) Lanthanum carbonate having more than six molecules of water per molecule of lanthanum carbonate with a particle size distribution such that d (0.9) is not more than 110 microns;

b) a pharmaceutically acceptable diluent or carrier except monosaccharide/s or disaccharide/s.

5. A pharmaceutical composition for the treatment of hyperphosphataemia comprising lanthanum carbonate having more than six molecules of water per molecule of lanthanum carbonate prepared by wet granulation technique, wherein said composition exhibits similar or higher phosphate binding capacity to that of commercially available FOSRENOL®.

6. A pharmaceutical composition according to any of the preceding claims, wherein percentage of lanthanum carbonate released from said dosage composition during in-vitro dissolution is comparable to that of lanthanum carbonate formulation marketed under the trade name of FOSRENOL®.

7. A pharmaceutical composition according to any of the preceding claims, wherein said lanthanum carbonate contains seven to ten molecules of water.

8. A pharmaceutical composition according to any of the preceding claims, wherein said composition is prepared by utilizing wet granulation technique and preferred granulating fluid is water.

9. A pharmaceutical composition according to any of the preceding claims wherein said pharmaceutically composition optionally contains one or more pharmaceutically acceptable excipients which include but not limited to carriers or diluents, binders, disintegrants, sweeteners, flovours, surfactants, glidants, and lubricantsT such that carrier or diluent excludes monosaccharide/s or disaccharide/s.

10. A pharmaceutical composition according to any of the preceding claims, wherein said composition comprises about 75% by weight of lanthanum carbonate octahydrate to the total weight of the composition.

11. A pharmaceutical composition according to any of the preceding claims, comprising lanthanum carbonate octahydrate, wherein lanthanum carbonate has a particle size distribution such that d (0.9) is not more than 80 microns.

12. A pharmaceutical composition according to any of the preceding claims, prepared by a process comprising the steps of:

a) blending lanthanum carbonate, at least one diluent or carrier and optionally other pharmaceutically acceptable excipients and granulating said mixture with a binder solution to form a granules;

b) optionally blending said granules with

i. one or more lubricant; ii. one or more extragranular component; and

c) compressing said final blend to form tablets.

13. A process as claimed in claim 12, wherein said diluent or carrier is selected form calcium carbonate, calcium phosphate-dibasic, calcium phosphate-tribasic, calcium sulfate, mannitol, microcrystalline cellulose, silicified microcrystalline cellulose and powdered cellulose.

14. A process as claimed in claim 12, wherein said pharmaceutically acceptable excipients include binders, disintegrants, sweeteners, flavours, surfactants, glidants and lubricants and preferably the binder is selected form methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, low substituted hydroxypropyl cellulose, hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, gelatin, polyvinylpyrrolidone and Eudragits.

Documents

Sign in to open
Application documents
1 737-CHE-2008 CORRESPONDENCE OTERS 26-03-2008.pdf 26 Mar 2008
2 737-CHE-2008 FORM-1 26-03-2008.pdf 26 Mar 2008
3 737-CHE-2008 DESCRIPTION (PROVISIONAL) 26-03-2008.pdf 26 Mar 2008
4 737-CHE-2008 FORM-3 15-04-2008.pdf 15 Apr 2008
5 737-CHE-2008 ABSTRACT 24-03-2009.pdf 24 Mar 2009
6 737-CHE-2008 FORM-5 24-03-2009.pdf 24 Mar 2009
7 737-CHE-2008 FORM-2 24-03-2009.pdf 24 Mar 2009
8 737-CHE-2008 FORM-1 24-03-2009.pdf 24 Mar 2009
9 737-CHE-2008 DRAWINGS 24-03-2009.pdf 24 Mar 2009
10 737-CHE-2008 DESCRIPTION (COMPLETE) 24-03-2009.pdf 24 Mar 2009
11 737-CHE-2008 CORRESPONDENCE OTHERS 24-03-2009.pdf 24 Mar 2009
12 737-CHE-2008 CLAIMS 24-03-2009.pdf 24 Mar 2009
13 737-CHE-2008 FORM-18 29-12-2009.pdf 29 Dec 2009
14 737-CHE-2008 FORM-3 10-11-2010.pdf 10 Nov 2010
15 737-CHE-2008 FORM-13 26-04-2011.pdf 26 Apr 2011
16 737-CHE-2008 FORM-3 08-08-2011.pdf 08 Aug 2011
17 737-CHE-2008 FORM-13 16-11-2011.pdf 16 Nov 2011
18 737-CHE-2008 FORM-3 25-08-2015.pdf 25 Aug 2015
19 737-CHE-2008 CORRESPONDENCE OTHERS 25-08-2015..pdf 25 Aug 2015
20 Examination Report Reply Recieved [17-11-2015(online)].pdf 17 Nov 2015
21 Description(Complete) [17-11-2015(online)].pdf 17 Nov 2015
22 Lanthanum FER reply Nov 17 2015.pdf 02 Jun 2016
23 Lanthanum CS.pdf 02 Jun 2016
24 737-CHE-2008_EXAMREPORT.pdf 02 Jul 2016
25 737-CHE-2008-Correspondence-060716.pdf 08 Jul 2016
26 737-CHE-2008-Correspondence-Assignment-Claims-290716.pdf 02 Aug 2016
27 737-CHE-2008-Claims-290716.pdf 02 Aug 2016
28 737-CHE-2008-ASSIGNMENT-290716.pdf 02 Aug 2016
29 Drawing_Granted 274796_09-08-2016.pdf 09 Aug 2016
30 Description_Granted 274796_09-08-2016.pdf 09 Aug 2016
31 Claims_Granted 274796_09-08-2016.pdf 09 Aug 2016
32 Abstract_Granted 274796_09-08-2016.pdf 09 Aug 2016
33 Form 27_Licence_24-03-2017.pdf 24 Mar 2017
34 737-CHE-2008-RELEVANT DOCUMENTS [26-03-2018(online)].pdf 26 Mar 2018
35 737-CHE-2008-RELEVANT DOCUMENTS [05-03-2019(online)].pdf 05 Mar 2019
36 737-CHE-2008-RELEVANT DOCUMENTS [30-03-2020(online)].pdf 30 Mar 2020
37 737-CHE-2008-RELEVANT DOCUMENTS [29-09-2021(online)].pdf 29 Sep 2021
38 737-CHE-2008-RELEVANT DOCUMENTS [05-09-2022(online)].pdf 05 Sep 2022
39 737-CHE-2008-RELEVANT DOCUMENTS [28-07-2023(online)].pdf 28 Jul 2023

ERegister / renewals

Inforce
3rd Renewed 18 Aug 2016 Period 26 Mar 2010 – 26 Mar 2011 · CBR 20764 · Certificate 13647 ₹4,000
4th Renewed 18 Aug 2016 Period 26 Mar 2011 – 26 Mar 2012 · CBR 20764 · Certificate 13648 ₹4,000
5th Renewed 18 Aug 2016 Period 26 Mar 2012 – 26 Mar 2013 · CBR 20764 · Certificate 13649 ₹4,000
6th Renewed 18 Aug 2016 Period 26 Mar 2013 – 26 Mar 2014 · CBR 20764 · Certificate 13650 ₹4,000
7th Renewed 18 Aug 2016 Period 26 Mar 2014 – 26 Mar 2015 · CBR 20764 · Certificate 13651 ₹12,000
8th Renewed 18 Aug 2016 Period 26 Mar 2015 – 26 Mar 2016 · CBR 20764 · Certificate 13652 ₹12,000
9th Renewed 01 Sep 2016 Period 26 Mar 2016 – 26 Mar 2017 · CBR 22306 · Certificate 14632 ₹12,000
10th Renewed 02 Sep 2016 Period 26 Mar 2017 – 26 Mar 2018 · CBR 22577 · Certificate 14898 ₹12,000
11th Renewed 02 Sep 2016 Period 26 Mar 2018 – 26 Mar 2019 · CBR 22577 · Certificate 14899 ₹24,000
12th Renewed 18 Mar 2019 Period 26 Mar 2019 – 26 Mar 2020 · CBR 8715 · Certificate 10736 ₹24,000
13th Renewed 12 Mar 2020 Period 26 Mar 2020 – 26 Mar 2021 · CBR 8883 · Certificate 15865 ₹24,000
14th Renewed 17 Mar 2021 Period 26 Mar 2021 – 26 Mar 2022 · CBR 9792 · Certificate 16849 ₹24,000
15th Renewed 15 Mar 2022 Period 26 Mar 2022 – 26 Mar 2023 · CBR 10152 · Certificate 17761 ₹24,000
16th Renewed 17 Mar 2023 Period 26 Mar 2023 – 26 Mar 2024 · CBR 12203 · Certificate 21516 ₹40,000
17th Renewed 15 Mar 2024 Period 26 Mar 2024 – 26 Mar 2025 · CBR 17804 · Certificate 53746 ₹40,000
18th Renewed 21 Mar 2025 Period 26 Mar 2025 – 26 Mar 2026 · CBR 16640 · Certificate 21656 ₹40,000
19th Renewed 13 Mar 2026 Period 26 Mar 2026 – 26 Mar 2027 · CBR 20011 · Certificate 20799 ₹40,000